BioCryst of­fi­cial­ly gets par­tial clin­i­cal hold on lead can­di­date af­ter halt­ing en­roll­ment

About a month af­ter BioCryst halt­ed three stud­ies for its oral Fac­tor D in­hibitor BCX9930, the FDA has im­posed a par­tial clin­i­cal hold.

The new de­vel­op­ment for the Durham, NC-based biotech was re­vealed in the biotech’s Q1 earn­ings an­nounce­ment Thurs­day morn­ing, and it end­ed up not say­ing much:

Sub­se­quent to BioCryst vol­un­tar­i­ly paus­ing tri­al en­roll­ments, the U.S. Food and Drug Ad­min­is­tra­tion (FDA) in­formed the com­pa­ny that it has placed the clin­i­cal pro­gram for BCX9930 on a par­tial clin­i­cal hold. Con­sis­tent with BioCryst’s vol­un­tary ac­tion, the com­pa­ny may not en­roll new pa­tients in its BCX9930 clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER